1668553-26-1
1668553-26-1 結(jié)構(gòu)式
基本信息
BIIB-024, TAK580, AMG-2112819, BSK1369, DAY-101
7-[5-[[4-[4-[(二甲基氨基)磺?；鵠-1-哌嗪基]苯氧基]甲基]-1,3-二甲基-1H-吡唑-4-基]-1-[2-(4-嗎啉基)乙基]-3-[3-(1-萘基氧基)丙基]-1H-吲哚-2-羧酸
CS-2202
A-1210477
Abbvie Mcl-1 Inhibitor
A-1210477
A 1210477
A1210477
7-(5-((4-(4-(N,N-dimethylsulfamoyl)piperazin-1-yl)phenoxy)methyl)-1,3-dimethyl-1H-pyrazol-4-yl)-1-(2-morpholinoethyl)-3-(3-(naphthalen-1-yloxy)propyl)-1H-indole-2-carboxylic acid
7-[5-[[4-[4-[(Dimethylamino)sulfonyl]-1-piperazinyl]phenoxy]methyl]-1,3-dimethyl-1H-pyrazol-4-yl]-1-[2-(4-morpholinyl)ethyl]-3-[3-(1-naphthalenyloxy)propyl]-1H-indole-2-carboxylic acid
1H-Indole-2-carboxylic acid, 7-[5-[[4-[4-[(dimethylamino)sulfonyl]-1-piperazinyl]phenoxy]methyl]-1,3-dimethyl-1H-pyrazol-4-yl]-1-[2-(4-morpholinyl)ethyl]-3-[3-(1-naphthalenyloxy)propyl]-
物理化學(xué)性質(zhì)
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2025/02/08 | HY-12468 | A-1210477 | 1668553-26-1 | 1 mg | 266元 |
| 2025/02/08 | HY-12468 | 7-(5-((4-(4-(N,N-二甲基氨基磺酰)哌嗪-1-基)苯氧基)甲基)-1,3-二甲基-1H-吡唑-4-基)-1-(2-嗎啉乙基)-3-(3-(萘-1-基氧基)丙基)-1H-吲哚-2-甲酸 A-1210477 | 1668553-26-1 | 5mg | 700元 |
| 2025/02/08 | HY-12468 | 7-(5-((4-(4-(N,N-二甲基氨基磺酰)哌嗪-1-基)苯氧基)甲基)-1,3-二甲基-1H-吡唑-4-基)-1-(2-嗎啉乙基)-3-(3-(萘-1-基氧基)丙基)-1H-吲哚-2-甲酸 A-1210477 | 1668553-26-1 | 10mg | 1200元 |
常見問(wèn)題列表
|
Mcl-1 0.45 nM (Ki) |
Bcl-2 132 nM (Ki) |
Bfl-1 660 nM (Ki) |
Bcl-W 2280 nM (Ki) |
Apoptosis
|
A-1210477 (10?μM) reduces the amount of BIM co-immunoprecipitated with MCL-1 antibody, and triggers MCL-1 elevation in a variety of cancer cell lines, including the breast cancer cell line HCC-1806. A-1210477 inhibits MCL-1-NOXA interactions with an IC 50 of approximately 1?μM, while having no effect on BCL-2-BIM or BCL-XL-BCL-XS interactions. The NSCLC cell lines H2110 and H23 are sensitive to A-1210477 with cell viability IC 50 <10?μM, confirming that A-1210477 can kill MCL-1-dependent cell lines.